Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen J Ambrose

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmacogenomics|September 12, 2002
SNPs and pharmacogenomicsHelen J Ambrose
Lancet (London, England)|December 25, 2007
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studiesEugene R Bleecker, Dirkje S Postma, Rachael M Lawrance, et al.
Respiratory Research|May 8, 2012
Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist responseHelen J Ambrose, Rachael M Lawrance, Carl J Cresswell, et al.
European Journal of Clinical Pharmacology|January 30, 2015
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United StatesBruce K Birmingham, Sarah R Bujac, Robert Elsby, et al.
European Journal of Clinical Pharmacology|February 13, 2015
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?Bruce K Birmingham, Sarah R Bujac, Robert Elsby, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmacogenomics|September 12, 2002
SNPs and pharmacogenomicsHelen J Ambrose
Lancet (London, England)|December 25, 2007
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studiesEugene R Bleecker, Dirkje S Postma, Rachael M Lawrance, et al.
Respiratory Research|May 8, 2012
Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist responseHelen J Ambrose, Rachael M Lawrance, Carl J Cresswell, et al.
European Journal of Clinical Pharmacology|January 30, 2015
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United StatesBruce K Birmingham, Sarah R Bujac, Robert Elsby, et al.
European Journal of Clinical Pharmacology|February 13, 2015
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?Bruce K Birmingham, Sarah R Bujac, Robert Elsby, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Pageof 1